LEADER 03292nam 2200661Ia 450 001 9910778330203321 005 20230721022539.0 010 $a0-309-14231-8 010 $a1-282-27265-9 010 $a9786612272653 010 $a0-309-13125-1 035 $a(CKB)1000000000789198 035 $a(OCoLC)427878159 035 $a(CaPaEBR)ebrary10327027 035 $a(SSID)ssj0000096382 035 $a(PQKBManifestationID)11121580 035 $a(PQKBTitleCode)TC0000096382 035 $a(PQKBWorkID)10076939 035 $a(PQKB)10857566 035 $a(MiAaPQ)EBC3378514 035 $a(Au-PeEL)EBL3378514 035 $a(CaPaEBR)ebr10327027 035 $a(CaONFJC)MIL227265 035 $a(OCoLC)923280588 035 $a(EXLCZ)991000000000789198 100 $a20090819d2009 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAccelerating the development of biomarkers for drug safety$b[electronic resource] $eworkshop summary /$fSteve Olson, Sally Robinson and Robert Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies 210 $aWashington, D.C. $cNational Academies Press$dc2009 215 $a1 online resource (99 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-309-13124-3 320 $aIncludes bibliographical references (p. 55-57). 327 $aOverview Of key issues -- Cardiac safety biomarkers -- Assessing and predicting kidney safety -- Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials -- Future considerations. 330 $a"Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held 'Assessing and Accelerating Development of Biomarkers for Drug Safety,' a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."--Publisher's website. 606 $aBiochemical markers$vCongresses 606 $aDrugs$xSafety measures$vCongresses 606 $aDrugs$xTesting$vCongresses 615 0$aBiochemical markers 615 0$aDrugs$xSafety measures 615 0$aDrugs$xTesting 676 $a616.075 701 $aGiffin$b Robert B$01510132 701 $aOlson$b Steve$f1956-$0488724 701 $aRobinson$b Sally$0620917 712 02$aNational Research Council (U.S.).$bPlanning Committee for Assessing and Accelerating the Development of Biomarkers for Drug Safety : a Workshop. 712 12$aAssessing and Accelerating the Development of Biomarkers for Drug Safety. Workshop$f(2008 :$eWashington, D.C.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910778330203321 996 $aAccelerating the development of biomarkers for drug safety$93831980 997 $aUNINA LEADER 01230nam0 22002651i 450 001 UON00123188 005 20231205102725.776 100 $a20020107d1970 |0itac50 ba 101 $aeng 102 $aIN 105 $a|||| 1|||| 200 1 $aTamil-Brahmi Inscriptions. [Lectures delivered by Thiru I. Mahadevam, at the Seminar on Archaeology, conducted by the Tamilnadu State Department of Archaeology, under the auspices of the Madurai University, in January 1970]$fThiru Iravatham Mahadevam 210 $aMadras$cState Department of Archaeology$d1970 215 $a15 p.$d22 cm 606 $aEPIGRAFIA INDIANA$xBRAHMI$3UONC001248$2FI 620 $aIN$dChennai$3UONL000058 686 $aSI XX A$cSUBCONT. INDIANO - EPIGRAFIA$2A 700 1$aMAHADEVAM$bThiru Iravatham$3UONV076855$0667349 712 $aTamilnadu State Department of Archaeology$3UONV262110$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00123188 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI SI XX A 020 Misc. a $eSI SA 7295 7 020 Misc. a 996 $aTamil-Brahmi Inscriptions.$91316281 997 $aUNIOR